PanTher Therapeutics is developing an implantable device that delivers cancer drugs directly to the tumour
The company’s first target for the implant is pancreatic cancer. Its CEO, Laura Indolfi told Fortune that PanTher is initially targeting this type of cancer because the pancreas has few blood vessels, which makes it more difficult for chemotherapy to reach the organ.
Indolfi, a recent TED fellow, said that targeting the tumour directly holds the promise of being more effective and could reduce the side effects that may occur elsewhere in the patient’s body.
PanTher has tested its device on animals to impressive results, Fortune reported and the company hopes to move on to human trials relatively soon.
Indolfi said to the news site: “We can go beyond pancreatic cancer. We hope we can address all solid tumours.”